European Journal of Surgical Oncology
Volume 36, Issue 4 , Pages 387-392 , April 2010

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: A comparison to conventional imaging techniques

  • T.S. Aukema

      Affiliations

    • Department of Nuclear Medicine, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 20 5122282; fax: +31 20 5122290.
    • ,
  • E.J.Th. Rutgers

      Affiliations

    • Department of Surgery, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • W.V. Vogel

      Affiliations

    • Department of Nuclear Medicine, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • H.J. Teertstra

      Affiliations

    • Department of Radiology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • H.S. Oldenburg

      Affiliations

    • Department of Surgery, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • M.T.F.D. Vrancken Peeters

      Affiliations

    • Department of Surgery, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • J. Wesseling

      Affiliations

    • Department of Pathology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • N.S. Russell

      Affiliations

    • Department of Radiotherapy, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    • ,
  • R.A. Valdés Olmos

      Affiliations

    • Department of Nuclear Medicine, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

,Accepted 16 November 2009.

References 

  1. Voogd AC, Nielsen M, Peterse JL, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol. 2001;19(6):1688–1697
  2. Van Tienhoven G, Voogd AC, Peterse JL, et al. Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC breast cancer cooperative group and the Danish Breast Cancer Cooperative Group. Eur J Cancer. 1999;35(1):32–38
  3. Aukema TS, Russell NS, Wesseling J, Rutgers EJ. Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: lasting local control and acceptable morbidity. Eur J Surg Oncol. 2009;35(5):469–474
  4. van Oost FJ, van der Hoeven JJ, Hoekstra OS, Voogd AC, Coebergh JW, van de Poll-Franse LV. Staging in patients with locoregionally recurrent breast cancer: current practice and prospects for positron emission tomography. Eur J Cancer. 2004;40(10):1545–1553
  5. Voogd AC, van Tienhoven G, Peterse HL, et al. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch study group on local recurrence after breast conservation (BORST). Cancer. 1999;85(2):437–446
  6. Haffty BG, Fischer D, Beinfield M, McKhann C. Prognosis following local recurrence in the conservatively treated breast cancer patient. Int J Radiat Oncol Biol Phys. 1991;21(2):293–298
  7. Halverson KJ, Perez CA, Kuske RR, Garcia DM, Simpson JR, Fineberg B. Survival following locoregional recurrence of breast cancer: univariate and multivariate analysis. Int J Radiat Oncol Biol Phys. 1992;23(2):285–291
  8. Gallowitsch HJ, Kresnik E, Gasser J, et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003;38(5):250–256
  9. Grahek D, Montravers F, Kerrou K, Aide N, Lotz JP, Talbot JN. [18F]-FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management. Eur J Nucl Med Mol Imaging. 2004;31(2):179–188
  10. Isasi CR, Moadel RM, Blaufox MD. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat. 2005;90(2):105–112
  11. Kamel EM, Wyss MT, Fehr MK, von Schulthess GK, Goerres GW. [18F]-Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 2003;129(3):147–153
  12. Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imag. 2004;31(7):932–939
  13. Antoch G, Saoudi N, Kuehl H, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004;22(21):4357–4368
  14. Abner AL, Recht A, Eberlein T, et al. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol. 1993;11(1):44–48
  15. Clark GM, Sledge GW, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987;5(1):55–61
  16. Dose J, Bleckmann C, Bachmann S, et al. Comparison of fluorodeoxyglucose positron emission tomography and “conventional diagnostic procedures” for the detection of distant metastases in breast cancer patients. Nucl Med Commun. 2002;23(9):857–864
  17. Mahner S, Schirrmacher S, Brenner W, et al. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer. Ann Oncol. 2008;19(7):1249–1254
  18. Schirrmeister H, Kuhn T, Guhlmann A, Santjohanser C, Horster T, Nussle K, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28(3):351–358
  19. Radan L, Ben Haim S, Bar-Shalom R, Guralnik L, Israel O. The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer. 2006;107(11):2545–2551
  20. Suarez M, Perez-Castejon MJ, Jimenez A, et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med. 2002;46(2):113–121
  21. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Pastorini F, Buzdar A. A retrospective study of first indicators of breast cancer recurrence. Oncology. 2000;58(3):185–190
  22. Viadana E, Cotter R, Pickren JW, Bross ID. An autopsy study of metastatic sites of breast cancer. Cancer Res. 1973;33(1):179–181
  23. Cook GJ, Houston S, Rubens R, Maisey MN, Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 1998;16(10):3375–3379
  24. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med. 2006;36(1):73–92
  25. Lonneux M, Borbath I, Berliere M, Kirkove C, Pauwels S. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging. 2000;3(2):45–49
  26. Yang SN, Liang JA, Lin FJ, Kao CH, Lin CC, Lee CC. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99 m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol. 2002;128(6):325–328
  27. Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]-fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26(29):4746–4751
  28. Veronesi U, De Cicco C, Galimberti VE, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18(3):473–478
  29. Aukema TS, Straver ME, Valdes Olmos RA, Vogel WV. A different role for FDG PET/CT in axillary lymph node staging in breast cancer. Eur J Nucl Med Mol Imag. 2009;36(11):1896–1897

PII: S0748-7983(09)00517-4

doi: 10.1016/j.ejso.2009.11.009

European Journal of Surgical Oncology
Volume 36, Issue 4 , Pages 387-392 , April 2010

Article Tools

* Image Usage & Resolution